Skip to main content
. 2021 Nov 10;11:22006. doi: 10.1038/s41598-021-01365-5

Table 2.

Perioperative features between bisoprolol and placebo groups.

Perioperative features Bisoprolol (N = 57) Placebo (N = 55) P value
Thoracic surgery 32 (56.1%) 31 (56.4%) 1.000
Thoracotomy/lobectomy 19 (33.3%) 15 (27.3%)
Video-assisted thoracoscopic surgery 13 (22.8%) 16 (29.1%)
Vascular surgery 25 (43.9%) 24 (43.6%) 1.000
Artery bypass graft 9 (15.8%) 10 (18.2%)
Abdominal aortic aneurysm repair 9 (15.8%) 6 (10.9%)
Percutaneous transluminal angioplasty 5 (8.8%) 6 (10.9%)
Anesthesia
 General 56 (98.2%) 52 (94.5%) 0.395
 Epidural or spinal 1 (1.8%) 3 (5.5%)
Preoperative hs-TNT (ng/L) 9.5 ± 10.6 9.5 ± 11.1 0.796
Postoperative peak hs-TNT (ng/L) 18.8 ± 19.6 15.7 ± 19.1 0.928
Preoperative NT-proBNP (ng/L) 122.6 ± 257.2 128.8 ± 270.6 0.571
Postoperative NT-proBNP (ng/L) 586.2 ± 703.0 370.0 ± 809.6 0.752
Preoperative hs-CRP (mg/L) 3.6 ± 25.0 4.2 ± 15.5 0.581
Postoperative hs-CRP (mg/L) 135.0 ± 100.1 111.0 ± 75.0 0.158
Preoperative creatinine (mg/dL) 1.2 ± 1.17 1.19 ± 1.16 0.616
Postoperative creatinine (mg/dL) 1.2 ± 1.4 1.0 ± 0.5 0.844
RCRI 0 40 (70.2%) 37 (67.3%) 0.906
RCRI 1 13 (22.8%) 15 (27.3%)
RCRI 2 2 (3.5%) 2 (3.6%)
RCRI 3 2 (3.5%) 1 (1.8%)

hs-CRP high-sensitive C-reactive protein, hs-TnT high-sensitive troponin-T, NT-proBNP N-terminal-pro B-type natriuretic peptide, RCRI revised cardiac risk index.